Publications by authors named "Katsumi Okane"
Article Synopsis
- Researchers created and validated a risk model for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with abiraterone acetate (ABI) to better predict patient outcomes.
- The study involved 233 patients from three academic centers and validated the model on a separate group of 282 patients, analyzing factors that influence progression-free survival (PFS2) and overall survival (OS).
- Key findings showed that the model effectively categorized patients into risk groups, with poor-risk patients having significantly lower median PFS2 and OS compared to favorable and intermediate groups, aiding in treatment planning.
Purpose: We assessed clinical outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with two upfront therapies.
Methods: The medical records of 301 patients with mCSPC treated with androgen deprivation therapy plus upfront abiraterone acetate (ABI) or docetaxel (DOC) between 2014 and 2021 were retrospectively reviewed. Propensity score matching (PSM) was performed to compare survival outcomes.
Article Synopsis
- Bacillus Calmette-Guerin (BCG) is a common treatment for high-risk non-muscle-invasive bladder cancer (NMIBC), but it often causes various adverse side effects.
- A study involving 106 Japanese patients investigated whether adding levofloxacin after BCG treatments could help reduce these side effects without affecting treatment effectiveness.
- The results showed that levofloxacin significantly lowered the rates of certain adverse events and was associated with better 5-year survival rates compared to BCG alone.
Purpose: This study investigated the impact of treatment intensification with upfront docetaxel (DOC) or abiraterone (ABI) plus prednisolone on survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) by comparing it with androgen deprivation therapy (ADT) monotherapy or combined androgen blockade (CAB) using propensity score matching (PSM).
Methods: Outcomes from 278 CHAARTED high-volume patients receiving upfront DOC (92 patients) or upfront ABI (186 patients) were compared to those from 354 patients receiving ADT or CAB. PSM was conducted to assess castration-resistant prostate cancer-free survival (CRPCFS) and overall survival (OS).
We conducted a risk-adapted upfront docetaxel (DOC) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Here, we reported an interim analysis of the study. The study enrolled 68 patients with newly diagnosed mHSPC between 2016 and 2018.
View Article and Find Full Text PDFA 37-year-old man was referred to our department for investigation of grosshematuria. Ultrasonography and computed tomography of the abdomen showed a mass in the urinary bladder. Emergency transurethral resection was performed for the control of bleeding.
View Article and Find Full Text PDF